YOLFTbeta
Proteina Co., Ltd.

Proteina Co., Ltd.

468530 · KQ · Healthcare / Biotechnology

58,100.00KRW+400.00 (+0.69%)

Price History

Full chart

Market Stats

Previous Close57,700.00
Open56,500.00
Day Range56,200.00 – 61,800.00
52-Week Range15,500.00 – 120,100.00
Volume159.34K
Market Cap561.20B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
50-Day Avg33,214.40
200-Day Avg55,215.85

About

Proteina Co., Ltd. develops protein-protein interaction profiling technology. The company offers technology that confirms the real-time activation of cancer signal pathways by directly seeing the relevant proteins, predicts the efficacy of drugs, and enables doctors to select which inhibitor to prescribe by confirming which bypass signal pathways are inducing resistance. It also offers single molecule protein interaction detection platform to analyze protein and protein-protein interaction (PPI) information. Proteina Co., Ltd. was founded in 2015 and is based in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Tae-Young Yoon Ph.D.
  • HeadquartersAce Techno Tower 8 #1301, Seoul, South Korea, 08380, Korea
  • Websitehttps://www.proteina.co.kr

Leadership

  • Dr. Tae-Young Yoon Ph.D.Founder, CEO & Representative Director · b. 1976
  • Dr. Ji Young Ryu Ph.D.Co-Founder, Chief Quality Officer & Executive Director · b. 1986
  • Mr. Dai Seung LeeCFO & Director · b. 1977
  • Dr. Hong Won Lee Ph.D.CTO & Executive Director · b. 1986
  • Dr. Jung Hyun Ahn Ph.D.Chief Science Officer
  • Mr. Steve HwangChief Communications Officer & IR Director · b. 1978
  • Mr. Jae Young KimChief Development Officer · b. 1975
  • Dr. Byung San Choi Ph.D.Chief Research Officer & Executive Director · b. 1989
  • Dr. Nayoung Kim Ph.D.Chief Business Development Officer · b. 1982

Financials

Income Statement

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Revenue465.62M578.13M2.30B2.95B
Growth (%)-+24.16%+297.96%+28.26%
Cost of Revenue-75.00M837.85M1.41B
Gross Profit465.62M503.13M1.46B1.54B
Gross Margin100.00%87.03%63.58%52.17%
Operating Expense5.84B7.76B10.58B12.91B
Operating Income-5.38B-7.26B-9.12B-11.37B
Operating Margin-1155.26%-1255.07%-396.45%-385.23%
EBITDA-8.62B-19.23B-1.63B-7.63B
EBITDA Margin-1850.83%-3325.80%-70.77%-258.65%
Net Income-11.37B-22.79B-5.73B-9.01B
Net Income Margin-2442.03%-3941.31%-249.23%-305.39%
R&D1.24B3.14B5.80B7.42B
R&D as % of Total Revenue265.32%542.87%251.97%251.52%
Interest Expense2.18B2.76B3.05B112.67M
Interest Expense % of Total Revenue468.40%477.57%132.71%3.82%

Balance Sheet

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Assets13.32B24.01B17.97B31.75B
Total Liabilities43.74B76.50B2.21B3.38B
Total Equity-30.42B-52.49B15.76B28.37B
Cash150.66M577.00M11.83B8.79B

Cash Flow

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.52B-5.68B-6.08B-8.07B
Capital Expenditure1.12B293.18M2.32B1.51B
Free Cash Flow-4.64B-5.98B-8.40B-9.58B
FCF to OCF131.86%105.16%138.10%118.66%

Earnings

Report DateSep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate----
EPS Actual-236.04-277.87-300.01-282.70
Surprise----
Timing----

Key Statistics & Ratios

Market Cap561.20B
Enterprise Value498.24B
Trailing P/E0.00
Forward P/E0.00
Price / Sales354.17
Price / Book22.78
Revenue (TTM)0
Gross Profit (TTM)0
Profit Margin0.00%
Operating Margin0.00%
Return on Equity0.00%
Return on Assets0.00%
Shares Outstanding10.94M
Shares Float0
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%